Parker Paul Gray 4

What Happened
Parker Paul Gray, a director of Generate Biomedicines, was granted a derivative award covering 29,561 shares on Feb 26, 2026. The filing reports an acquisition at $0.00 (i.e., no cash paid at grant). The award is a compensation/award grant (not an open‑market purchase or sale) and will vest in full on February 19, 2027, subject to Gray's continued service.

Key Details

• Transaction date: 2026-02-26; Form 4 filed: 2026-03-02 (appears timely — within 2 business days).
• Security: derivative award covering 29,561 shares; reported price $0.00.
• Vesting: vests in full on 2027-02-19 subject to continued service (footnote).
• Shares owned after transaction: not specified in the filing.
• No 10b5-1 plan, tax withholding, or late‑filing footnotes were reported.

Context
This was a compensation grant to a director rather than a purchase or sale by the insider. Such awards are common for director compensation and do not represent an immediate change in selling or buying pressure (the shares vest in the future). Retail investors typically view grants as part of routine compensation; purchases by insiders tend to be more direct signals of personal conviction.